Skip to main content

CASE REPORT article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1497736
This article is part of the Research Topic Innovative Immunotherapy Strategies for Enhanced Treatment of Hodgkin and Non-Hodgkin Lymphomas View all 9 articles

A novel third-generation anti-CD19/CD22 CAR T-cells combined with auto-HSCT for relapsed Burkitt lymphoma

Provisionally accepted
XIAODAN LUO XIAODAN LUO 1Ao Chen Ao Chen 1Le Qin Le Qin 2Robert Weinkove Robert Weinkove 3Rong Zhao Rong Zhao 1Ting Ye Ting Ye 1Sihui Chen Sihui Chen 1Jianli Tang Jianli Tang 1Jianbo Liu Jianbo Liu 1Jiayu Huang Jiayu Huang 1Boyun Shi Boyun Shi 1Danyun Yuan Danyun Yuan 1Huo Tan Huo Tan 1Dajiang Qin Dajiang Qin 1Zhaoyang Tang Zhaoyang Tang 2Peng Li Peng Li 2*Runhui Zheng Runhui Zheng 1*
  • 1 Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
  • 2 Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CAS), Guangzhou, Guangdong Province, China
  • 3 Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand

The final, formatted version of the article will be published soon.

    This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy.A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.

    Keywords: relapsed/refractory Burkitt lymphoma, CAR T-cell therapy, Autologous hematopoietic stem cell transplantation, CD19/CD22 dual target, Immunotherapy

    Received: 17 Sep 2024; Accepted: 20 Nov 2024.

    Copyright: © 2024 LUO, Chen, Qin, Weinkove, Zhao, Ye, Chen, Tang, Liu, Huang, Shi, Yuan, Tan, Qin, Tang, Li and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Peng Li, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CAS), Guangzhou, 510530, Guangdong Province, China
    Runhui Zheng, Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.